Download full-text PDF

Source

Publication Analysis

Top Keywords

[long-term splenectomy
4
splenectomy thalassemia
4
thalassemia major]
4
[long-term
1
thalassemia
1
major]
1

Similar Publications

The spleen in ischaemic heart disease.

Nat Rev Cardiol

January 2025

Institute for Pathophysiology, West German Heart and Vascular Center, University of Duisburg-Essen, Essen, Germany.

Article Synopsis
  • Ischaemic heart disease results from coronary atherosclerosis, which is linked to systemic inflammation involving various immune cells released by the spleen.
  • Prolonged inflammation can lead to ischaemic heart failure, while the spleen's interaction with the nervous system can modulate immune responses and protect the heart from damage.
  • Splenectomy, which removes the spleen, increases mortality risk from ischaemic heart disease, highlighting the spleen's crucial role in immune responses and cardiovascular protection.
View Article and Find Full Text PDF

Gastric mixed adenoneuroendocrine carcinoma (MANEC) is a rare and highly aggressive malignancy characterized by both exocrine and neuroendocrine components. Treatment options for metastatic cases are limited, with typical therapeutic approaches involving a combination of chemotherapy and immunotherapy. A 68-year-old male with metastatic gastric MANEC was treated with targeted therapy, immunotherapy, and chemotherapy, including S-1, apatinib, cadonilimab, and paclitaxel.

View Article and Find Full Text PDF

Background Beta-thalassemia major is a genetic blood disease complicated by splenomegaly, and splenectomy is a standard therapy for this medical condition. Although splenectomy results not only in the improvement of the hematological status, the long-term consequences to the cardiovascular system are still questionable. Objective The aim of the study was to assess and compare the cardiovascular impact of splenomegaly and splenectomy in patients with beta-thalassemia major.

View Article and Find Full Text PDF

Proximal splenorenal shunt is the most commonly performed shunt in patients with extrahepatic portal venous obstruction (EHPVO). Sometimes, due to various anatomical and intraoperative factors, other rarely used shunts may be required. We present the case of a 27-year-old male who was diagnosed with EHPVO with complicated portal cavernomatous cholangiopathy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!